Ferric sulfate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ferric sulfate
Accession Number
DB11171
Type
Small Molecule
Groups
Approved
Description

Ferric sulfate has the molecular formula of Fe2SO4, and it is a dark brown or yellow chemical agent with acidic properties. It is produced by the reaction of sulfuric acid and an oxidizing agent. It is used in different fields such as dermatology, dentistry and it is thought to present hemostatic properties by interacting chemically with blood proteins.1,2 By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).6

Structure
Thumb
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Ferric cationionic91O4LML61120074-52-6VTLYFUHAOXGGBS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FasTRACT Topical HemostatGel142 mg/1IntragingivalCao Group, Inc.2016-02-082018-10-11Us
FastStat Topical HemostatGel142 mg/1gIntragingivalCao Group, Inc.2010-09-012018-10-11Us
Statis Hemostyptic Soln 210mg/mlLiquid210 mgDentalGingi Pak Labs, Division Of Belport Co., Inc.1986-12-312004-08-16Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ferrostat Liq 21%Liquid21 %DentalHoechst Roussel Canada Inc.1995-12-311997-11-19Canada
Hemodent FSLiquid15.5 %TopicalPremier Dental Products Company1997-12-101998-07-02Canada
StasisSolution3150 mg/15mLDental; Oral; PeriodontalGingi-Pak a Division of the Belport1987-06-26Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FasTRACT Topical HemostatFerric sulfate (142 mg/1)GelIntragingivalCao Group, Inc.2016-02-082018-10-11Us
FastStat Topical HemostatFerric sulfate (142 mg/1g)GelIntragingivalCao Group, Inc.2010-09-012018-10-11Us
StasisFerric sulfate (3150 mg/15mL)SolutionDental; Oral; PeriodontalGingi-Pak a Division of the Belport1987-06-26Not applicableUs
Categories
UNII
3HWS7HF5XD
CAS number
10028-22-5
Weight
Average: 489.93
Monoisotopic: 489.777884
Chemical Formula
Fe2H10O17S3
InChI Key
YHGPYBQVSJBGHH-UHFFFAOYSA-H
InChI
InChI=1S/2Fe.3H2O4S.5H2O/c;;3*1-5(2,3)4;;;;;/h;;3*(H2,1,2,3,4);5*1H2/q2*+3;;;;;;;;/p-6
IUPAC Name
diiron(3+) ion pentahydrate trisulfate
SMILES
O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O

Pharmacology

Indication

Ferric sulfate was first used in dermatology as part of the Monsel's solution. This solution is an antihemorrhagic agent used in skin and mucosal biopsies. The use of ferric sulfate in dermatology is under review as ferric sulfate is corrosive and injurious and it can cause degenerative changes that are not observed with other alternatives like collagen.3

Ferric sulfate is also used as a coagulative and hemostatic agent. It is a mechanic hemostatic agent used directly on the damaged tissue.1

In dentistry, ferric sulfate is used as a pulpotomy medicament to control pulpal bleeding, as an antibacterial agent and as a hemostatic reagent for restorative dentistry, for postextraction hemorrhage and for periradicular and endodontic surgery.2

Pharmacodynamics

The administration of ferric sulfate as a dermatologic agent has showed delayed reepithelialization and dyspigmentation. Some studies have reported the generation of inflammation in the sites of administration of ferric sulfate.2

Mechanism of action

The main function of ferric sulfate is as a hemostatic agent in different medical practices. This hemostatic function is achieved when ferric sulfate is applied directly in the damaged tissue. Once applied, ferric sulfate forms ferric ion-protein complex which helps the sealing of the damaged vessels mechanically. The formation of agglutinated protein complexes produces the generation of occlusion in the capillary orifices.4 The formation of the ferric protein complex is thought to be due to a chemical reaction between the acidic form of ferric sulfate and the blood proteins.5

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Pharmacokinetic studies related to the absorption of ferric sulfate have not been performed.

Volume of distribution

Pharmacokinetic studies related to the volume of distribution of ferric sulfate have not been performed.

Protein binding

Ferric sulfate presents very high protein binding properties, this property is thought to be due to its acidic profile.5

Metabolism

Pharmacokinetic studies related to the metabolism of ferric sulfate have not been performed.

Route of elimination

Pharmacokinetic studies related to the elimination of ferric sulfate have not been performed.

Half life

Pharmacokinetic studies related to the half-life of ferric sulfate have not been performed.

Clearance

Pharmacokinetic studies related to the clearance of ferric sulfate have not been performed.

Toxicity

Ferric sulfate has been proven to be an irritating substance into the eye, throat, gastrointestinal and respiratory tract.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3-Aza-2,3-Dihydrogeranyl DiphosphateFerric sulfate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidFerric sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
AloglutamolAloglutamol can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Nouri S, Sharif MR: Use of ferric sulfate to control hepatic bleeding. Trauma Mon. 2015 Feb;20(1):e25257. doi: 10.5812/traumamon.25257. Epub 2015 Jan 1. [PubMed:25825702]
  2. Bandi M, Mallineni SK, Nuvvula S: Clinical applications of ferric sulfate in dentistry: A narrative review. J Conserv Dent. 2017 Jul-Aug;20(4):278-281. doi: 10.4103/JCD.JCD_259_16. [PubMed:29259368]
  3. Olmstead PM, Lund HZ, Leonard DD: Monsel's solution: a histologic nuisance. J Am Acad Dermatol. 1980 Nov;3(5):492-8. [PubMed:7217377]
  4. EPSTEIN E, MAIBACH HI: MONSEL'S SOLUTION; HISTORY, CHEMISTRY, AND EFFICACY. Arch Dermatol. 1964 Aug;90:226-8. [PubMed:14162333]
  5. Smith NL, Seale NS, Nunn ME: Ferric sulfate pulpotomy in primary molars: a retrospective study. Pediatr Dent. 2000 May-Jun;22(3):192-9. [PubMed:10846729]
  6. FDA Code of Federal Regulations [Link]
External Links
PubChem Compound
23443659
PubChem Substance
347827931
ChemSpider
11640309
Wikipedia
Iron(III)_sulfate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableActive Not RecruitingTreatmentPrimary Teeth / Pulpotomy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
GelIntragingival142 mg/1
GelIntragingival142 mg/1g
LiquidDental21 %
LiquidTopical15.5 %
SolutionDental; Oral; Periodontal3150 mg/15mL
LiquidDental210 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)The Anhydrous form decomposes (480ºC) 'MSDS'
boiling point (°C)The Anhydrous form decomposes (480ºC) 'MSDS'
water solubilitySoluble at room temperatureBandi, et al. J Conserv Dent. (2017)
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as transition metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal oxoanionic compounds
Sub Class
Transition metal sulfates
Direct Parent
Transition metal sulfates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Transition metal sulfate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on December 03, 2015 09:51 / Updated on July 13, 2019 00:55